市場調查報告書
商品編碼
1029318

RNA 干擾 (RNAi) 藥物遞送的全球市場:行業趨勢、份額、規模、增長、機會、預測(2021-2026)

RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 142 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球 RNA 干擾 (RNAi) 藥物遞送市場預計從 2015 年到 2020 年將強勁增長,2021 年到 2026 年的複合年增長率為 22.8%。世界範圍內癌症和心血管疾病等慢性病和遺傳性疾病的增加是推動市場增長的重要因素之一。此外,易患此類疾病的老年人口的增加也是市場增長的一個因素。在這方面,隨著 COVID-19 繼續在全球範圍內傳播,對 RNAi 藥物遞送技術的需求顯著增加。

適配體藥物遞送系統等靶向遞送方法是由可以抑制病毒抗原表達的小干擾RNA(siRNA)誘導的,並獲得了抗病毒藥物給藥的巨大支持。此外,各種技術進步,例如創新合成遞送載體和生物載體的開發,預計將推動市場增長。納米載體,包括 siRNAs 和 microRNAs (miRNAs),對於個性化藥物的開發以及改變細胞分子和代謝物的鑑定至關重要。

本報告調查了全球 RNA 干擾 (RNAi) 藥物輸送市場,包括市場表現、COVID-19 的影響、按應用/技術/地區進行的市場分析、競爭形勢、主要公司簡介等。提供了有關信息。

目錄

第一章前言

第二章範圍和調查方法

第 3 章執行摘要

第 4 章介紹

第 5 章全球 RNA 干擾 (RNAi) 藥物遞送市場

  • 市場概覽
  • 市場表現
  • COVID-19 的影響

第 6 章按應用細分市場

  • 傳染病
  • 心臟病
  • 腫瘤
  • 神經
  • 眼睛
  • 泌尿外科
  • 代謝紊亂
  • 其他

第 7 章按技術細分市場

  • 納米顆粒給藥
  • 經肺給藥
  • 核酸藥物遞送
  • 適體藥物遞送

第 8 章按地區劃分的市場細分

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 印度尼西亞
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 按國家/地區劃分的市場細分

第 9 章 SWOT 分析

第10章價值鏈分析

第11章波特五力分析

第12章價格分析

第十三章競爭形勢

  • 市場結構
  • 主要公司
  • 主要公司簡介
    • Alnylam Pharmaceuticals Inc.
    • Arrowhead Pharmaceuticals Inc.
    • CureVac AG
    • Dicerna Pharmaceuticals Inc.
    • Gradalis Inc.
    • Ionis Pharmaceuticals Inc
    • Merck & Co. Inc.
    • Moderna Inc.
    • Quark Pharmaceuticals Inc.(SBI ALApharma Co. Limited)
    • Silence Therapeutics Plc
    • Sirnaomics Inc.
目錄
Product Code: SR1020F268_Report

The global RNA interference (RNAi) drug delivery market exhibited strong growth during 2015-2020. Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.

The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further. Looking forward, IMARC Group expects the global RNA interference (RNAi) drug delivery market to grow at a CAGR of 22.8% during 2021-2026.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global rna interference (rnai) drug delivery market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, application and technology.

Breakup by Application:

  • Infectious Disease
  • Cardiology
  • Oncology
  • Neurology
  • Ophthalmology
  • Urology
  • Metabolic Disorders
  • Others

Breakup by Technology:

  • Nanoparticle Drug Delivery
  • Pulmonary Drug Delivery
  • Nucleic Acid Drug Delivery
  • Aptamer Drug Delivery

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc and Sirnaomics Inc.

Key Questions Answered in This Report:

  • How has the global RNA interference (RNAi) drug delivery market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global RNA interference (RNAi) drug delivery market?
  • What are the key regional markets?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the technology?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global RNA interference (RNAi) drug delivery market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global RNA Interference (RNAi) Drug Delivery Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Application

  • 6.1 Infectious Disease
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cardiology
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Oncology
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Neurology
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Ophthalmology
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Urology
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Metabolic Disorders
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Nanoparticle Drug Delivery
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Pulmonary Drug Delivery
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Nucleic Acid Drug Delivery
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Aptamer Drug Delivery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Alnylam Pharmaceuticals Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Arrowhead Pharmaceuticals Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 CureVac AG
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
    • 13.3.4 Dicerna Pharmaceuticals Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
    • 13.3.5 Gradalis Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Ionis Pharmaceuticals Inc
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Merck & Co. Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Moderna Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
    • 13.3.10 Silence Therapeutics Plc
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
    • 13.3.11 Sirnaomics Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio

List of Figures

  • Figure 1: Global: RNA Interference (RNAi) Drug Delivery Market: Major Drivers and Challenges
  • Figure 2: Global: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015-2020
  • Figure 3: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Application (in %), 2020
  • Figure 4: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Technology (in %), 2020
  • Figure 5: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Region (in %), 2020
  • Figure 6: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 7: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 8: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 9: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 10: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 11: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 12: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 13: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 14: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 15: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 16: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 17: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 18: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 19: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 20: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 21: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 22: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 23: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 24: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 25: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 26: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 27: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 28: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 29: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 30: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 31: North America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 32: North America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 33: United States: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 34: United States: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 35: Canada: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 36: Canada: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 37: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 38: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 39: China: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 40: China: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 41: Japan: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 42: Japan: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 43: India: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 44: India: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 45: South Korea: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 46: South Korea: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 47: Australia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 48: Australia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 49: Indonesia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 50: Indonesia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 51: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 52: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 53: Europe: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 54: Europe: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 55: Germany: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 56: Germany: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 57: France: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 58: France: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 59: United Kingdom: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 60: United Kingdom: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 61: Italy: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 62: Italy: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 63: Spain: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 64: Spain: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 65: Russia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 66: Russia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 67: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 68: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 69: Latin America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 70: Latin America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 71: Brazil: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 72: Brazil: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 73: Mexico: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 74: Mexico: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 75: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 76: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 77: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 78: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 79: Global: RNA Interference (RNAi) Drug Delivery Industry: SWOT Analysis
  • Figure 80: Global: RNA Interference (RNAi) Drug Delivery Industry: Value Chain Analysis
  • Figure 81: Global: RNA Interference (RNAi) Drug Delivery Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: RNA Interference (RNAi) Drug Delivery Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Application (in Million US$), 2021-2026
  • Table 3: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Technology (in Million US$), 2021-2026
  • Table 4: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 5: Global: RNA Interference (RNAi) Drug Delivery Market Structure
  • Table 6: Global: RNA Interference (RNAi) Drug Delivery Market: Key Players